The total volume in each dental cartridge is stated as 1.7 mL by most of the manufacturers; however, most of the dental literature refers to the volume as 1.8 mL. When maximum dosages are calculated and expressed in terms of the number of carpules/cartridges, this may be fundamentally flawed due to the inherent difference in the total volume.

Table 1 gives a summary of the maximum recommended dosage of various anesthetic agents regarding the volume of the cartridge of choice. ^, Readers should take into consideration that these values are not claimed to be compensatory for the ineptness or lack of operator skills during the administration of the LA.

Vasoconstrictors, notably epinephrine, are added in LA formulations in standard concentrations typically ranging from 1:50,000 to 1:100,000. The appropriate concentration is contingent upon the specific LA agent utilized. In patients with cardiovascular conditions, the dose of epinephrine is recommended to be maintained at 0.04 mg (2 cartridges of 1.8 mL of 2% Lidocaine with 1:100,000 epinephrine). It is imperative to consider several pivotal cases, particularly in patients whose underlying medical conditions may influence the pharmacokinetics and pharmacodynamics of the anesthetic, including advanced pregnancy, specific cardiovascular pathologies, and uremia, among others.

Table 2 gives a summary of epinephrine concentration in carpules of various volumes, used globally. ^,

Combining LA agents can enhance the efficacy, duration, and onset of anesthesia by leveraging the unique benefits of each agent. However, differences in pH can affect the potency and toxicity of the mixture, posing serious risks in the event of an overdose. Hence, it is advisable to limit the total administered dose to no more than 100% of the combined maximum allowable dosages for each agent. While this guideline is sensible, it currently lacks strong empirical support. Therefore, careful clinical judgment and patient monitoring are essential when utilizing combinations of LA agents. ^,

Dentistry currently has enough LA formulations other than articaine and bupivacaine that can justifiably be used in nerve blocks. The responsibility of the decision to use either of these agents in an inferior alveolar nerve (IAN) block, for example, lies solely with the clinician. When the clinician must defend themselves in case of an adverse drug reaction, a legitimate question would be, did they “have to” use the specific agent, and most of the time the answer would be a definitive “no.” Hence, there is current caution against using these agents in nerve blocks. However, we could not find a consensus against the usage either in private practice or across the dental institutions. There is no conclusive evidence; the decision stays with the dentist. ^,

Propofol has limited analgesic properties; however, owing to its favorable characteristics, such as antiemetic effects and accelerated recovery compared with midazolam, among others, it is still widely employed in general anesthesia procedures. A dosage of up to 6 mg/kg/h has been recommended; however, lower doses (<3 mg/kg/h) may also effectively sedate the patient and reduce bodily movement. Given that lower doses minimize the risk of desaturation, the dosage should be titrated and catered to the individual patient’s needs. Propofol is administered via slow injection, starting with a loading dose of 0.5 to 1 mg/kg intravenous (IV), followed by additional 0.5 mg/kg IV doses every 3 to 5 minutes as needed. The narrow therapeutic window and heightened sensitivity of children to sedatives may result in inadvertent oversedation, necessitating that only qualified personnel administer IVS in the pediatric population. The safety of propofol has not yet been substantiated for pregnant women and children under 3 years of age. ^,, Adverse effects include hypotension and respiratory suppression, among others. ^, Official documents on the recommended doses in anesthesia procedures in dental schools could not be found.

Specific guidelines for the maximum dose of midazolam in dental practice have not been established. As a result, dental professionals typically follow the maximum dose of 7.5 mg, as recommended by the British National Formulary (BNF). ^,, The benzodiazepine reversal agent flumazenil must be available when starting the anesthesia with midazolam. It is our anecdotal finding that the regulations and practice procedures on the usage of midazolam are widely varied in various US dental schools.

Dentists are responsible for approximately 9% of all opioid prescriptions in the United States. Dental opioid prescriptions are a known gateway to misuse, especially in adolescents. While a single prescribed dose may not cause physiologic dependence, initial exposure can increase susceptibility to misuse and long-term use. Approximately 7% of adolescents and young adults who filled a prescription after third molar extraction continued to fill prescriptions months later, indicating a link between first exposure in dental settings and persistent use. Genetic predisposition has also been shown to influence an individual’s risk of opioid misuse and dependency, with variations in drug metabolism and brain reward pathways playing a significant role. The necessity of opioid prescription in dentistry is currently controversial. The clinician should follow the Centers for Disease Control and Prevention (CDC) and other pertinent guidelines.

Midazolam has generally received positive feedback from patients for optimal sedation with a moderate cardiac safety profile. The recommended dose for the adult population is 0.25 to 0.5 mg/kg orally, less than 30 minutes prior to the procedure, with the maximum dose being 20 mg. It is contraindicated in pregnancy and is classified under category D. If given intravenously postdelivery, nursing should be restricted until the drug has been eliminated from the mother’s system. Subsequently, the baby needs to be monitored for the side effects of the drug. ^,

For optimal management of medically compromised patients with anxiety, sedatives can be administered orally prior to any procedure.

There are no standardized antibiotics recommended to treat odontogenic infections. Most practitioners predominantly prescribe amoxicillin due to its broad-spectrum action as opposed to penicillin V, a narrow-spectrum antibiotic. ^, The use of clindamycin is prevalent, particularly in countries such as Germany. In dentistry, antibiotics are deemed a nonsurgical therapeutic modality in cases of pulpitis, dry socket, and periapical infections, among others. This can lead to antimicrobial resistance or elicit allergic responses. Discrepancies have also been noted in various journals in the United Kingdom, accounting for the antibiotic of choice and its span of administration. Antibiotics are not indicated in healthy adults with pulpal necrosis or apical periodontitis, without swelling or systemic involvement. If there is systemic involvement and/or acute apical abscess, antibiotics may be indicated as an adjunct to definitive conservative dental treatment. This latest guideline/standard of care forms the foundation for dentists to potentially minimize antibiotic resistance.

AAPD recommends amoxicillin for pediatric patients who require antibiotic coverage. Doxycycline is the drug of choice in children who are allergic to penicillin, macrolides, and cephalosporins. In cases of penicillin allergy, azithromycin is the drug of choice; however, the incidence of cardiotoxicity is prevalent. Although guidelines have been laid down by AAPD, many practitioners continue to prescribe antibiotics when not indicated. The rationale behind this is due to a lack of knowledge among dentists, patients’ desires, and inconsistencies in their appointments. Discrepancies when elucidating the children’s medical history also contributed to the fallacy.

Inconsistencies have been noted regarding the calibration of antibiotics. Infections of pulpal and periodontal origin, without systemic spread, need to be managed locally or surgically, without the use of antibiotics. Build-up of antibiotic resistance is an iatrogenic consequence due to a lack of aforementioned awareness.